ABSTRACT
Within the contemporary state of affairs we all realize the significance of wearing a masks, though we are wear a mask, in some situations we're affected to Covid. In that case our mask is designed in a way which is multilayered and reusable. The primary gain of our masks is that we're setting a breathing sensor (humidity sensor) within the masks so that any sort of respiratory trouble may be detected in a much simpler way with the use of blue tooth. In order too that respiration troubles of human beings may be quarantined and spreading may be stopped at the primary level itself. The ongoing 2nd wave of Covid 19 pandemics has ended in an global scarcity of face mask and the uncooked chemical compounds that move into them, prompting humans to make their personal mask from of regular items. N95/p2 respiration masks are one of the vital components for decreasing the spread of the Covid 19 virus and shielding frontline humans. With the wearable multi layer air cleanser masks our idea is to replace it with homemade masks worn through many and also which are disposable and reusable ones. The layout also makes it viable to wear the unit with no trouble for hours on give up. This might be made light-weight so that users can utilise it with ease. Further survey has been made among a group of people by wearing our mask and their humidity level has been noted thorough the software developed. © 2023 Author(s).
ABSTRACT
OBJECTIVE: Undoubtfully, COVID-19 vaccine (C19V) has significantly changed the pandemic's trajectory positively. At the same time, reports of transient local and systemic post-vaccination reactions leave a concern about its unknown impact on common ailments. Its effect on IARI is unclear because the present IARI epidemic began immediately after C19V in the previous season. PATIENTS AND METHODS: A retrospective observational cohort study among 250 Influenza-associated respiratory infection (IARI) patients by a structured interview questionnaire was conducted with the comparison between 3 groups with 1 dose, 2 doses and 2 doses plus booster dose of C19V. The p<0.05 was considered significant in this study. RESULTS: Among samples 21.2% received one dose of the C19V, only 3.6% got Flu vaccination, 30% had ≥2 comorbidities such as diabetes (22.8%), hypertension (28.4%) and ionically, 77.2% were on chronic medications. Significant differences (p<0.05) were found between groups with duration of illness, cough, headache, fatigue, shortness of breath and hospital visits. The logistic regression analysis shows that the extended IARI symptoms and hospital visits were significantly high among Group 3 (OR=9.17, 95% CI=3.01-29.0) and the same trend remained significant after adjusting the incidence of comorbidities among samples, the chronic conditions (OR=5.13, 95% CI=1.37-14.91) and flu vaccination status (O=4.96, 95% CI=1.41-16.2). Also, 66.4% of the patients were indecisive about getting vaccinated further. CONCLUSIONS: It has been challenging to reach any definitive conclusions regarding the effects of C19V on IARI, conducting extensive, substantial population-based studies that integrate clinical and virological data from more than one season is absolutely required, despite the fact that the majority of the reported effects were mild and temporary.